Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2005

View Archived Issues

Serotonin 5-HT7 receptor as a target for depression and other psychiatric diseases

Dendritic cell-targeted immunosuppressive actions of JM-34

Antipsychotic efficacy of bifeprunox mesilate

Cytos Biotechnology and Medarex expand collaboration

BioTie and sanofi-aventis to negotiate extension of agreement to develop oral heparin-like product

Halozyme files an NDA for Enhanze SC

Osiris cleared to begin stem cell trial for knee repair

Sepracor to launch Lunesta

Treatment begins in phase III study of tolevamer in CDAD

Phase III trial completed for Bio-E-Gel

Acorda launches Zanaflex Capsules

Novel PAR-2 antagonists presented by Kowa

Nuvelo and Kirin to develop NU-206

T-817MA alleviates oxidative stress in rat cortical neurons

Ligand earns milestone from TAP's IND filing

Recent Roche patents describe therapeutic agents for genitourinary disorders

Novel antiarthritic agents imparted by Cellular Genomics

New treatments for cardiovascular disorders claimed in recent patent literature

Japanese sales release of Zione Injection products

Peptide YY3-36 reduces food intake through taste aversion

Janus files IND for JA-001

Adoptive cell transfer demonstrates activity in metastatic melanoma patients

ATPase studied in new phase II trial

Curis and Genentech form second major collaboration

Phase III study of VP-002 for central precocious puberty completes enrollment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...